<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060134</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-0004</org_study_id>
    <nct_id>NCT04060134</nct_id>
  </id_info>
  <brief_title>A Retrospective Breast Reconstruction Study</brief_title>
  <official_title>A Retrospective, Multi-Center, Open Label Study Evaluating SimpliDermâ„¢ and Other Human Acellular Dermal Matrices in Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziyo Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziyo Biologics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect data on patients who have previously undergone breast reconstruction utilizing
      SimpliDerm and other HADMs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a retrospective, multi-center, open label study evaluating SimpliDerm and other
      human acellular dermal matrices in breast reconstruction.

      A total of up to 300 patients who underwent direct to implant (one stage) or two-stage
      unilateral or bilateral breast reconstruction with SimpliDerm an other HADMs at the time of
      implant or TE placement.

      Data will be collected for a minimum of one post-surgical visit after direct implant or
      exchange. If more visits are available, data from those visits will be collected as well.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Events</measure>
    <time_frame>From date of surgery through study completion, an average of 9 months</time_frame>
    <description>Occurrence of: infection, hematoma, seroma, capsular contracture, mastectomy skin flap dehiscence, mastectomy skin flap necrosis, expander/implant explantation, red breast syndrome, subsequent surgical interventions related to the breast reconstruction process</description>
  </primary_outcome>
  <other_outcome>
    <measure>Integration Assessment</measure>
    <time_frame>From date of surgery through study completion, an average of 9 months</time_frame>
    <description>Integration assessment for patients with two-stage reconstruction at time of exchange, if available, via surgeon's operative notes</description>
  </other_outcome>
  <other_outcome>
    <measure>Drain Removal</measure>
    <time_frame>From date of surgery through study completion, an average of 9 months</time_frame>
    <description>Time to drain removal and volume of fluid drained, if available</description>
  </other_outcome>
  <other_outcome>
    <measure>Intraoperative fill volume</measure>
    <time_frame>From date of surgery through study completion, an average of 9 months</time_frame>
    <description>Intraoperative fill volume</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HADM</arm_group_label>
    <description>Patients who had human acellular dermal matrix used in their breast reconstruction procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HADM</intervention_name>
    <description>Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.</description>
    <arm_group_label>HADM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of up to 300 female patients, who had direct to implant
        or two-stage immediate breast reconstruction following unilateral or bilateral mastectomy
        surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient who underwent immediate breast reconstruction post-mastectomy; either
             direct to implant or with a tissue expander followed by exchange for a saline or gel
             implant.

          -  HADMs such as: InteguPly, SimpliDerm, AlloDerm, FlexHD, DermACELL, Cortiva, or AlloMax
             used in the breast reconstruction.

        Exclusion Criteria:

          -  Female patient who underwent cosmetic/aesthetic breast augmentation procedure or
             revision.

          -  Female patient who underwent delayed breast reconstruction procedure.

          -  Female patient who underwent revision of previous breast reconstruction procedure.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Richardson</last_name>
    <phone>678-492-4712</phone>
    <email>srichardson@aziyo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shawn Piasecki, PhD</last_name>
    <email>spiasecki@aziyo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoals Plastic Surgery</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Inmon</last_name>
      <email>gina.inmon@shoalshospital.com</email>
    </contact>
    <investigator>
      <last_name>George R Jennings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension/Seton Institute of Reconstructive Plastic Surgery</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Weinfeld, MD</last_name>
      <phone>512-324-2765</phone>
    </contact>
    <contact_backup>
      <last_name>Kristina Adrean</last_name>
      <phone>512-324-9999</phone>
      <phone_ext>10025</phone_ext>
      <email>kadrean@ascension.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>DHR Health</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aidee Nunez</last_name>
      <email>a.nunez@dhr-rgv.com</email>
    </contact>
    <investigator>
      <last_name>Mauricio De La Garza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aziyo.com</url>
    <description>Aziyo Biologics, Inc.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

